Cargando…

Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A)

BACKGROUND: Laminin-α2-deficient congenital muscular dystrophy (MDC1A) is a severe muscle-wasting disease for which no curative treatment is available. Antagonists of the angiotensin II receptor type 1 (AT1), including the anti-hypertensive drug losartan, have been shown to block also the profibroti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meinen, Sarina, Lin, Shuo, Ruegg, Markus A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598380/ https://www.ncbi.nlm.nih.gov/pubmed/22943509 http://dx.doi.org/10.1186/2044-5040-2-18

Ejemplares similares

Linker molecules between laminins and dystroglycan ameliorate laminin-α2–deficient muscular dystrophy at all disease stages
por: Meinen, Sarina, et al.
Publicado: (2007)

Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A)
por: Vohra, Ravneet, et al.
Publicado: (2015)

Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice
por: Meinen, Sarina, et al.
Publicado: (2011)

Cobblestone Malformation in LAMA2 Congenital Muscular Dystrophy (MDC1A)
por: Jayakody, Himali, et al.
Publicado: (2020)

Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy
por: Willmann, Raffaella, et al.
Publicado: (2017)

Zebrafish Models of LAMA2-Related Congenital Muscular Dystrophy (MDC1A)
por: Fabian, Lacramioara, et al.
Publicado: (2020)

Widening the spectrum of LAMA 2 congenital muscular dystrophy (MDC1A): cobblestone malformation
por: Borella, Luiz Fernando Monte, et al.
Publicado: (2021)

Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy
por: Mehuron, Thomas, et al.
Publicado: (2014)

Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy
por: Nguyen, Quynh, et al.
Publicado: (2019)

Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies
por: Gawlik, Kinga I, et al.
Publicado: (2011)

Correction: dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy
por: Mehuron, Thomas, et al.
Publicado: (2014)

Laminin and Integrin in LAMA2-Related Congenital Muscular Dystrophy: From Disease to Therapeutics
por: Barraza-Flores, Pamela, et al.
Publicado: (2020)

Immortalized myogenic cells from congenital muscular dystrophy type1A patients recapitulate aberrant caspase activation in pathogenesis: a new tool for MDC1A research
por: Yoon, Soonsang, et al.
Publicado: (2013)

Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
por: Pasteuning-Vuhman, S., et al.
Publicado: (2018)

An atypical expression of core α-Dystroglycan and Laminin-α2 in skin fibroblasts of patients with congenital muscular dystrophies
por: Sabry, Sahar, et al.
Publicado: (2023)

Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A
por: Domi, Teuta, et al.
Publicado: (2015)

Nerve pathology is prevented by linker proteins in mouse models for LAMA2-related muscular dystrophy
por: Reinhard, Judith R, et al.
Publicado: (2023)

Antioxidants Reduce Muscular Dystrophy in the dy(2J)/dy(2J) Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
por: Harandi, Vahid M., et al.
Publicado: (2020)

Early skeletal muscle pathology and disease progress in the dy(3K)/dy(3K) mouse model of congenital muscular dystrophy with laminin α2 chain-deficiency
por: Gawlik, Kinga I., et al.
Publicado: (2019)

Fukuyama Congenital Muscular Dystrophy
por: Agarwal, Amit, et al.
Publicado: (2022)

Bortezomib Does Not Reduce Muscular Dystrophy in the dy(2J)/dy(2J) Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
por: Körner, Zandra, et al.
Publicado: (2016)

Autophagy increase in Merosin-Deficient Congenital Muscular Dystrophy type 1A
por: Mastrapasqua, Mariangela, et al.
Publicado: (2023)

Long-term follow-up of laminin α2 (merosin)-deficient muscular dystrophy in a cat
por: Awamura, Yuichi, et al.
Publicado: (2008)

Micro-laminin gene therapy can function as an inhibitor of muscle disease in the dy(W) mouse model of MDC1A
por: Packer, Davin, et al.
Publicado: (2021)

Fatigue and Muscle Atrophy in a Mouse Model of Myasthenia Gravis Is Paralleled by Loss of Sarcolemmal nNOS
por: Meinen, Sarina, et al.
Publicado: (2012)

Diagnostic approach to the congenital muscular dystrophies
por: Bönnemann, Carsten G., et al.
Publicado: (2014)

Immobilization of Dystrophin and Laminin α2-Chain Deficient Zebrafish Larvae In Vivo Prevents the Development of Muscular Dystrophy
por: Li, Mei, et al.
Publicado: (2015)

Laminin α2 Deficiency-Related Muscular Dystrophy Mimicking Emery-Dreifuss and Collagen VI related Diseases
por: Nelson, Isabelle, et al.
Publicado: (2015)

Merosin-deficient congenital muscular dystrophy type 1A: A case report
por: HE, ZHANWEN, et al.
Publicado: (2013)

Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy
por: Mucha, Olga, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy
por: Howard, Zachary M., et al.
Publicado: (2022)

Congenital muscular dystrophy type 1A with residual merosin expression
por: Kim, Hyo Jeong, et al.
Publicado: (2014)

Congenital Muscular Dystrophies: A Brief Review
por: Bertini, Enrico, et al.
Publicado: (2011)

Congenital muscular dystrophy with inflammation: Diagnostic considerations
por: Konkay, Kaumudi, et al.
Publicado: (2016)

Congenital muscular dystrophy: from muscle to brain
por: Falsaperla, Raffaele, et al.
Publicado: (2016)

Genetic and Clinical Advances of Congenital Muscular Dystrophy
por: Fu, Xiao-Na, et al.
Publicado: (2017)

Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency
por: Pane, M., et al.
Publicado: (2012)

Ovine congenital progressive muscular dystrophy (OCPMD) is a model of TNNT1 congenital myopathy
por: Clayton, Joshua S., et al.
Publicado: (2020)

COL4A1 mutations: new route to congenital muscular dystrophy
Publicado: (2011)

Congenital Muscular Dystrophy due to POMGNT1 Mutation Presenting as Cardioembolic Stroke
por: Iype, Mary, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q54bg7g6vti6rbijgmkukmuevk